Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc.SNOA · Entity 8177 | Chief Executive Officer | July 09, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sonoma Pharmaceuticals, Inc.
Report date July 09, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 52,185 |
Reported balance
After 2026-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 10,000 · Balance 52,185 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock. F3: The RSUs were awarded and granted to Ms. Trombly for services performed. F2: The RSUs vest on the third anniversary of the grant date, or upon change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
F2: The RSUs vest on the third anniversary of the grant date, or upon change of control.
F3: The RSUs were awarded and granted to Ms. Trombly for services performed.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 10, 2026 00:47 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-005422 · ownership.xml · derivative · entry 1 Trombly Amy Moss · CIK 0001384640 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,185 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock. F3 · price: The RSUs were awarded and granted to Ms. Trombly for services performed. F2 · derivative.exercise_date: The RSUs vest on the third anniversary of the grant date, or upon change of control. F2 · derivative.expiration_date: The RSUs vest on the third anniversary of the grant date, or upon change of control. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 22:24 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-000042 · ownership.xml · derivative · entry 1 Trombly Amy Moss · CIK 0001384640 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,185 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock. F3 · price: The RSUs were awarded and granted to Ms. Trombly for services performed. F2 · derivative.exercise_date: The RSUs vest on the third anniversary of the grant date, or upon change of control. F2 · derivative.expiration_date: The RSUs vest on the third anniversary of the grant date, or upon change of control. Read SEC document |
| June 19, 2025 Filed Jun 20, 2025 21:00 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantRestricted Stock Units · Derivative | 13,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-004661 · ownership.xml · derivative · entry 1 Trombly Amy Moss · CIK 0001384640 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,185 Underlying: Common Stock · 13,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock. F3 · price: The RSUs were awarded and granted to Ms. Trombly for services performed. F2 · derivative.exercise_date: The RSUs vest on the third anniversary of the grant date, or upon change of control. F2 · derivative.expiration_date: The RSUs vest on the third anniversary of the grant date, or upon change of control. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:02 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-000081 · ownership.xml · derivative · entry 1 Trombly Amy Moss · CIK 0001384640 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,685 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock. F3 · price: The RSUs were awarded and granted to Ms. Trombly for services performed as part of the Company's annual equity grant. F2 · derivative.exercise_date: The RSUs vest one-third each on July 2, 2025, July 2, 2026 and January 2, 2027, or upon change of control. F2 · derivative.expiration_date: The RSUs vest one-third each on July 2, 2025, July 2, 2026 and January 2, 2027, or upon change of control. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 21:06 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantCommon Stock, $0.0001 par value | 53,586 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-24-004426 · ownership.xml · nonDerivative · entry 1 Trombly Amy Moss · CIK 0001384640 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,586 F1 · price: The shares of common stock were awarded and granted as Restricted Stock Units to Ms. Trombly for services performed as part of the Company's annual bonus compensation to executives. The shares vested in full on the grant date. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 22:26 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 60,000 | Not disclosed Strike: $0.18 | Not disclosed |
DisclosureSEC source: 0001683168-23-009158 · ownership.xml · derivative · entry 1 Trombly Amy Moss · CIK 0001384640 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,648 Underlying: Common Stock · 60,000 shares Expires 2033-12-29 F2 · price: The options were awarded and granted to Ms. Trombly for services performed as part of the Company's annual grant of stock options. F1 · derivative.exercise_date: The options vest one third each on 12/29/2024, 12/29/2025 and 12/29/2026, or upon change of control or as provided by Ms. Trombly's employment agreement. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 21:00 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantCommon Stock, $0.0001 par value | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-23-004632 · ownership.xml · nonDerivative · entry 1 Trombly Amy Moss · CIK 0001384640 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,648 F1 · price: The shares of common stock were awarded and granted to Ms. Trombly for services performed as part of the Company's annual bonus compensation to executives. Read SEC document |
| December 29, 2022 Filed Dec 30, 2022 22:01 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001683168-22-008720 · ownership.xml · derivative · entry 1 Trombly Amy Moss · CIK 0001384640 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,648 Underlying: Common Stock · 40,000 shares Expires 2032-12-29 F2 · price: The options were awarded and granted to Ms. Trombly for services performed as part of the Company's annual grant of stock options. F1 · derivative.exercise_date: The options vest one third each on 12/29/2023, 12/29/2024 and 12/29/2025, or upon change of control or as provided by Ms. Trombly's employment agreement. Read SEC document |
| January 14, 2022 Filed Jan 15, 2022 01:33 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001683168-22-000279 · ownership.xml · derivative · entry 1 Trombly Amy Moss · CIK 0001384640 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,648 Underlying: Common stock · 30,000 shares Expires 2032-01-14 F2 · price: The options were awarded and granted to Ms. Trombly for services performed. F1 · derivative.exercise_date: The options vest 10,000 each on 07/14/2022, 07/14/2023 and 07/14/2024, or upon change of control. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:16 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 27,777 | Not disclosed Strike: $8.03 | Not disclosed |
DisclosureSEC source: 0001683168-21-000065 · ownership.xml · derivative · entry 1 Trombly Amy Moss · CIK 0001384640 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,648 Underlying: Common Stock · 27,777 shares Expires 2031-01-07 F2 · price: The options were awarded and granted to Ms. Trombly for services performed. F1 · derivative.exercise_date: The options vest one third each on 01/07/2022, 01/07/2023 and 01/07/2024, or upon change of control. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:03 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 2,380 | Not disclosed Strike: $4.55 | Not disclosed |
DisclosureSEC source: 0001683168-20-000020 · ownership.xml · derivative · entry 2 Trombly Amy Moss · CIK 0001384640 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,871 Underlying: Common Stock · 2,380 shares Expires 2021-01-02 F2 · price: The options were awarded and granted to Ms. Trombly for services performed. F3 · derivative.exercise_date: The options vest in two equal tranches: the first half vest on 7/2/2020 and the remaining half vest on 1/2/2021. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:03 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 13,491 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001683168-20-000020 · ownership.xml · derivative · entry 1 Trombly Amy Moss · CIK 0001384640 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,491 Underlying: Common stock · 13,491 shares Expires 2019-12-31 F2 · price: The options were awarded and granted to Ms. Trombly for services performed. F1 · derivative.exercise_date: The options vest in two equal tranches: the first half vest on 7/1/2020 and the remaining half vest on 12/31/2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.